Athersys Inc. (ATHX)
Symbol Info
Listed Symbol ATHX
Name Athersys Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $23,738,000
Latest Fiscal EPS $-0.18
Price Info
21 Day Moving Average $1.3557
21 Day EMA $1.362060
50 Day Moving Average $1.3586
50 Day EMA $1.386790
200 Day EMA $1.539090
200 Day Moving Average 1.515450
52 Week High $2.15
52 Week Low $1.20
52 Week Change $-36.190502
Alpha 0.011508
Beta 0.3051
Standard Deviation 0.174172
R2 0.003619
Periods 60
Share Information
10 Day Average Volume 289,107
20 Day Average Volume 389,924
30 Day Average Volume 450,202
50 Day Average Volume 474,372
Outstanding Shares 152,677,751
Float Shares 148,578,558
Percent Float 97.32%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 166
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 3,855,925
Institute Holdings Percent 35.300000
Institute Sold Previous 3 Months 2,744,551
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 13
Insider Holdings Percent 2.70%
Insider Sold Previous 3 Months -
Insiders Shares Owned 4,099,193
Price Change
7 Day Price Change $-0.03
7 Day Percent Change -2.19%
21 Day Price Change $0.0100000
21 Day Percent Change 0.75%
30 Day Price Change $-0.13
30 Day Percent Change -8.84%
Month To Date Price Change $0.0100
Month To Date Percent 0.75%
90 Day Price Change $-0.15
90 Day Percent Change -10.07%
Quarter To Date $0.010000
Quarter To Date Percent 0.75%
180 Day Price Change $-0.05
180 Day Percent Change -3.60%
200 Day Price Change $-0.16
200 Day Percent Change -10.67%
Year To Date $-0.1
Year To Date Percent -6.94%
Profile
Description Athersys Inc is a clinical stage biotechnology company. It is focused on developing novel and proprietary therapies in the areas where there is significant unmet medical need, particularly in the regenerative medicine area. The firm's main product is Multistem cell therapy. Its current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.
Details
Issue Type CS
Market Cap $204,588,186
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 152,677,751
CEO Gil Van Bokkelen
Employees 75
Last Audit UE
Classification
CIK 0001368148
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 3201 Carnegie Avenue
Cleveland, OH 44115-2634
Website http://www.athersys.com
Facisimile +1 216 361-9495
Telephone +1 216 431-9900
Email info@athersys.com
Key Ratios
Profitability
EBIT Margin -468.4
EBITDA Margin -459.8
Pre-Tax Profit Margin -514.4
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $7,058,000
Revenue Per Share $0.0462
Revenue 3 Years $-14.01
Revenue 5 Years $82.14
Valuation Measures
PE Ratio -
Enterprise Value $158,824,408
Price To Sales 28.986706
Price To Free Cash -9.1
PE High Last 5 Years -
Price To Book 6.0
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 6.0
Financial Strength
Total Debt To Equity -
Int Coverage -
Current Ratio 3.3
Leverage Ratio 1.7
Quick Ratio 3.2
Long Term Debt To Capital -
Assets
Receivables Turnover 0.6
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -69.29
Return On Equity -97.66
Return On Capital -97.66
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
ATHX
Athersys
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.